H. J. Klümpen

Learn More
Background Assessment of clinical benefit of systemic treatments of rare diseases including gastroenteropancreatic neuroendocrine tumours (GEP-NET) is challenging. Recently several tools have been(More)
Importance To our knowledge, this is the first randomized clinical trial evaluating an alternating treatment regimen in an attempt to delay disease progression in clear cell renal cell carcinoma. (More)
TPS175 Background: Treatment strategy in early HCC is directed to the local removal of the tumor (resection, liver transplantation, RFA, PEI) with the attempt to cure the disease. In intermediate and(More)